Burman and Zuckerbrod Ophthalmology is proud to announce that we’re one of only 14 practices nationwide offering the groundbreaking Lumithera Valeda treatment for dry macular degeneration (AMD). Recently approved by the FDA, this innovative therapy manages a condition that’s one of the leading causes of vision loss, particularly in people over 50. Lumithera Valeda offers a new hope for those facing the gradual loss of central vision due to dry AMD.
The Lumithera Valeda system utilizes photobiomodulation therapy, a cutting-edge technique that applies low-level light to the retina to stimulate mitochondrial activity within retinal cells. This process helps reduce oxidative stress, ease inflammation, and support cellular repair. By doing so, it potentially slows the progression of dry macular degeneration while improving overall retinal health.
The FDA’s approval of Lumithera Valeda marks an exciting breakthrough for people living with dry AMD. We’re excited to offer this cutting-edge treatment as a new option for vision care.
If you or a loved one is affected by dry macular degeneration, we invite you to contact us to learn more about how Lumithera Valeda can help. Reach out to our office at (248) 332-4544, and let us guide you through this innovative treatment today.